Word: bristols
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
Whether out of sheer benevolence or a desire to end its public relations woes, Bristol-Meyers-Squibb Pharmaceuticals announced last week that it would market its AIDS drugs, Zerit and Videx, to Africa at a combined price of $1 per day. This follows closely on the heels of Merck Pharmaceuticals' announcement that it would market its drug, the protease inhibitor Crixivan, to Africa at the reduced price of $600 per year. AIDS drugs typically cost between $10,000 and $15,000 per year. Needless to say, because of these exorbitantly high prices, these drugs are out of reach for those...
...pharmaceutical companies went to court to keep generic copies of their drugs out of South Africa, one of the biggest of these, Merck, announced it would slash prices of two of its major AIDS drugs, Crixivan and Stocrin, an additional 40% to 55%. Other drug giants--including GlaxoSmithKline and Bristol-Myers Squibb--immediately signaled they would follow suit...
...used to think plaques were like bits of concrete scattered throughout the brain," says Bristol-Myers' Molinoff. "But there's now intriguing evidence that suggests you can get plaque regression." Some of the most striking evidence comes from studies of a vaccine against beta amyloid that Schenk and his co-workers at Elan have developed. In 1999 they administered their vaccine to mice whose brains were filled with plaques. A short time later, the plaques shrank. Currently the Elan vaccine, like the Bristol-Myers' secretase inhibitor, is in early-phase clinical trials, in which the primary objective is to test...
...process, including some old-line drugs that have turned out to have antiangiogenic properties. Thalidomide, which caused devastating birth defects in some 12,000 children worldwide before it was withdrawn in the early 1960s, is finding a new lease on life against multiple myeloma and liver cancers. Pharmaceutical giant Bristol-Myers Squibb is testing an antiangiogenic drug that was initially developed to keep cancer from worming its way into surrounding tissue. It's also investigating whether low, steady doses of traditional chemotherapy may be able to beat back blood vessels, a treatment that would have the added benefit of minimal...
...pulls cholesterol that has already been manufactured out of a cell. "By turning this reverse cholesterol transport on, you'd be able to stimulate removal of cholesterol from vessel walls back to the liver for excretion," says Dr. Richard Gregg, vice president of metabolic- and cardiovascular-drug discovery at Bristol-Myers Squibb. Taken in combination with statins, such drugs could virtually sweep the arteries clean of cholesterol...